GlassScriptPhysician profile
Parshotam Lal
NPI 1538325642
$1,407.75
in general payments reported to CMS, 2019-2025
26 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $254 · 2021: $92.85 · 2022: $228 · 2023: $112 · 2024: $94.68 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $307.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $275.52 | 2019-2024 | Trulance, Xifaxan |
| Novo Nordisk INC | $136.63 | 2022-2025 | Ozempic, Rybelsus |
| Allergan, INC. | $124.28 | 2019-2020 | |
| Vifor Pharma, INC. | $69.53 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $67.58 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $65.95 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $57.86 | 2020-2024 | Farxiga |
| Pfizer INC. | $57.01 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $50.48 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.59 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $43.02 | 2019 | |
| Abbott Laboratories | $42.70 | 2021-2023 | Freestyle Libre |
| Lilly USA, LLC | $42.41 | 2022-2023 | Mounjaro, Trulicity |
| Abbvie INC. | $39.99 | 2022-2023 | |
| Esperion Therapeutics, INC. | $38.18 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $30.82 | 2025 | Shingrix |
| Amgen INC. | $28.14 | 2021-2022 | |
| Tetraphase Pharmaceuticals, INC. | $27.29 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $26.76 | 2019 | |
| Averitas Pharma INC. | $26.53 | 2025 | Qutenza |
| Janssen Pharmaceuticals, INC | $24.55 | 2019-2020 | |
| Dexcom, INC. | $20.32 | 2024 | Dexcom G6 Transmitter |
| Alkermes, INC. | $18.47 | 2019 | |
| Mylan Specialty L.P. | $15.88 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.72 | 2023 | |
| Insmed, INC. | $14.54 | 2024 | Arikayce |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parshotam Lal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.